Ajanta Pharma Limited — Q2 FY26
Ajanta Pharma delivered a strong Q2 FY26 with revenue of INR 1,354 crore (+14% YoY) and PAT of INR 260 crore (+20% YoY).
bullish
high
Financial stats pending filing verification
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY26
US generics run-rate to sustain at current level for FY26
Management expects the current quarterly run-rate of ~INR 310 crore to continue for the remaining three quarters, supported by existing limited-competition products and 2-3 more launches planned.
Delivered
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
heuristic_v1
Q1 FY26
India business to grow 20-25% higher than IPM growth
India business aims to grow at 10%+ if IPM grows at 8%, maintaining its outperformance trajectory.
Delivered
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
heuristic_v1